MA27332A1 - Compositions pharmaceutiques amorphes electroniquement filees. - Google Patents

Compositions pharmaceutiques amorphes electroniquement filees.

Info

Publication number
MA27332A1
MA27332A1 MA28092A MA28092A MA27332A1 MA 27332 A1 MA27332 A1 MA 27332A1 MA 28092 A MA28092 A MA 28092A MA 28092 A MA28092 A MA 28092A MA 27332 A1 MA27332 A1 MA 27332A1
Authority
MA
Morocco
Prior art keywords
leaded
electronically
pharmaceutical compositions
amorphous pharmaceutical
amorphous
Prior art date
Application number
MA28092A
Other languages
English (en)
Inventor
Linghong Sun
Francis Ignatious
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA27332A1 publication Critical patent/MA27332A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • D01D5/0007—Electro-spinning
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Textile Engineering (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)

Abstract

La présente invention se rapporte à l'utilisation de l'électrofilage, c-à-d. le procédé de fabrication de nanofibres polymères à partir d'une solution ou d'une substance fondue sous des forces électriques, afin de préparer des dispersions solides stables de médicaments amorphes dans des nanofibres polymères. Nombre de lignes : 1454
MA28092A 2002-08-07 2005-02-04 Compositions pharmaceutiques amorphes electroniquement filees. MA27332A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40172602P 2002-08-07 2002-08-07

Publications (1)

Publication Number Publication Date
MA27332A1 true MA27332A1 (fr) 2005-05-02

Family

ID=31715724

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28092A MA27332A1 (fr) 2002-08-07 2005-02-04 Compositions pharmaceutiques amorphes electroniquement filees.

Country Status (20)

Country Link
US (1) US20060013869A1 (fr)
EP (1) EP1534250A4 (fr)
JP (1) JP2005534716A (fr)
KR (1) KR20050055696A (fr)
CN (1) CN1684673A (fr)
AR (1) AR040820A1 (fr)
AU (1) AU2003258120B2 (fr)
BR (1) BR0313222A (fr)
CA (1) CA2494865A1 (fr)
IL (1) IL166465A0 (fr)
IS (1) IS7722A (fr)
MA (1) MA27332A1 (fr)
MX (1) MXPA05001499A (fr)
NO (1) NO20051123L (fr)
NZ (1) NZ537951A (fr)
PL (1) PL374800A1 (fr)
RU (1) RU2331411C2 (fr)
TW (1) TW200410714A (fr)
WO (1) WO2004014304A2 (fr)
ZA (1) ZA200500563B (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
CA2492084A1 (fr) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Hydobromure de carvedilol
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
US20080262224A1 (en) * 2004-01-23 2008-10-23 Smithkline Beecham Corporation Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide
ES2245874B1 (es) * 2004-03-22 2007-08-01 Universidad De Sevilla Procedimiento para generar nanotubos y nanofibras compuestas a partir de chorros coaxiales.
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
EP1863547B1 (fr) 2005-03-11 2016-05-11 Wake Forest University Health Sciences Vaisseaux sanguins realises par genie tissulaire
US20060204539A1 (en) 2005-03-11 2006-09-14 Anthony Atala Electrospun cell matrices
US8728463B2 (en) 2005-03-11 2014-05-20 Wake Forest University Health Science Production of tissue engineered digits and limbs
US7531503B2 (en) 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
EP1863546B1 (fr) 2005-03-11 2015-10-07 Wake Forest University Health Sciences Production par genie tissulaire de valvules cardiaques
CN1300393C (zh) * 2005-07-01 2007-02-14 中国科学院长春应用化学研究所 超细纤维药物剂型的乳液电纺丝制备方法
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008023818A1 (fr) * 2006-08-25 2008-02-28 Sekisui Chemical Co., Ltd. Fibre et procédé de production de fibre
GB0623473D0 (en) 2006-11-24 2007-01-03 Bristol Myers Squibb Co Dissolution and processing of cellulose
JP2010513324A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
EP2016076A2 (fr) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Formes polymorphes d'hydrobromure de rosiglitazone et leurs procédés de préparation
US20090326128A1 (en) * 2007-05-08 2009-12-31 Javier Macossay-Torres Fibers and methods relating thereto
US20100018641A1 (en) * 2007-06-08 2010-01-28 Kimberly-Clark Worldwide, Inc. Methods of Applying Skin Wellness Agents to a Nonwoven Web Through Electrospinning Nanofibers
WO2009050190A2 (fr) * 2007-10-15 2009-04-23 Glaxo Group Limited Dispositifs de liaison pour formes posologiques à éléments multiples et permettant l'administration d'une ou plusieurs compositions pharmaceutiques, et formes posologiques en résultant
JP5190515B2 (ja) * 2007-10-15 2013-04-24 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ 充填リンカーを製造する方法および装置
CN101827572A (zh) * 2007-10-15 2010-09-08 葛兰素集团有限公司 用于释放药物组合物的有板条的胶囊壳
EA027333B1 (ru) * 2007-10-17 2017-07-31 Тодд Ф. Овокайтис Стабильный при комнатной температуре некристаллический аспирин
US8765170B2 (en) 2008-01-30 2014-07-01 The Procter & Gamble Company Personal care composition in the form of an article
AU2009236166A1 (en) 2008-04-16 2009-10-22 The Procter & Gamble Company Non-lathering personal care composition in the form of an article
US20110174158A1 (en) * 2008-05-13 2011-07-21 Research Triangle Institute Particle filter system incorporating electret nanofibers
EP2328567A2 (fr) 2008-08-08 2011-06-08 Basf Se Structures planes fibreuses à base de biopolymères qui contiennent un principe actif, leurs applications et leurs procédés de production
WO2010015709A2 (fr) 2008-08-08 2010-02-11 Basf Se Structures planes fibreuses contenant un principe actif et à libération réglable du principe actif, leurs applications et leurs procédés de production
CN101721751B (zh) * 2008-10-10 2013-01-02 张阳德 负载了缓释细胞生长因子的具有内核的中空二氧化硅球的人体组织工程支架及其制法和用途
US20100291165A1 (en) * 2008-12-08 2010-11-18 Glenn Jr Robert Wayne Personal care composition in the form of an article having a hydrophobic surface-resident coating
US20100144228A1 (en) * 2008-12-09 2010-06-10 Branham Kelly D Nanofibers Having Embedded Particles
GB2466073A (en) * 2008-12-12 2010-06-16 Univ Manchester Tissue repair scaffold
WO2010071595A1 (fr) * 2008-12-19 2010-06-24 Sekab Biofuels & Chemicals Ab Liquide à base d'éthanol contenant un dénaturant
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
GB2468503A (en) * 2009-03-11 2010-09-15 Univ Sheffield A dressing comprising an electrospun scaffold and a nonsteroidal anti-inflammatory drug
GB0908433D0 (en) * 2009-05-15 2009-06-24 Glaxo Group Ltd Movel composition
WO2011029777A1 (fr) 2009-09-11 2011-03-17 Basf Se Procédés de production de fibres polymères enduites
CN102647972B (zh) * 2009-12-08 2013-12-11 宝洁公司 可溶性多孔固体基质和包含基质微球体的表面驻留涂层
KR20120117912A (ko) * 2010-02-15 2012-10-24 코넬 유니버시티 전기방사 장치 및 이로부터 제조된 나노섬유
US9173826B2 (en) 2010-02-16 2015-11-03 The Procter & Gamble Company Porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione
JP6113072B2 (ja) * 2010-07-02 2017-04-12 ザ プロクター アンド ギャンブル カンパニー パーソナルケア物品の製造方法
CN102959150B (zh) 2010-07-02 2016-08-03 宝洁公司 包含可摄取活性剂的长丝、非织造纤维网及其制备方法
JP5324709B2 (ja) * 2010-07-02 2013-10-23 ザ プロクター アンド ギャンブル カンパニー 活性剤不織布ウェブを含むフィラメント及びその製造方法
CN103025929B (zh) 2010-07-02 2015-11-25 宝洁公司 包含活性剂的长丝、非织造纤维网和制备它们的方法
EP2588655B1 (fr) 2010-07-02 2017-11-15 The Procter and Gamble Company Procédé de diffusion d'un agent actif
EP2588654B1 (fr) 2010-07-02 2019-08-07 The Procter and Gamble Company Matériau non-tissé comprenant un ou plusieurs agents actifs
US20180163325A1 (en) 2016-12-09 2018-06-14 Robert Wayne Glenn, Jr. Dissolvable fibrous web structure article comprising active agents
MX2012015169A (es) * 2010-07-02 2013-05-09 Procter & Gamble Filamentos que comprenden un agente activo sin perfume, tramas de tela no tejida y métodos para elaborarlos.
JP6203639B2 (ja) * 2011-01-28 2017-09-27 メリット・メディカル・システムズ・インコーポレイテッドＭｅｒｉｔ Ｍｅｄｉｃａｌ Ｓｙｓｔｅｍｓ，Ｉｎｃ． 電界紡糸されたｐｔｆｅでコーティングされたステントおよび使用方法
US9102570B2 (en) 2011-04-22 2015-08-11 Cornell University Process of making metal and ceramic nanofibers
CA2834212C (fr) 2011-04-29 2019-05-14 Massachusetts Institute Of Technology Traitement de couche pour des produits pharmaceutiques
JP6135870B2 (ja) * 2011-05-02 2017-05-31 ディーエスエム アイピー アセッツ ビー．ブイ． 生分解性ポリマーを含む繊維
EP2537538A1 (fr) * 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Pansement biorésorbable
CN102462673A (zh) * 2011-07-22 2012-05-23 广东食品药品职业学院 一种自组装囊泡载药纳米纤维膜及其电纺制备方法
RU2487701C2 (ru) * 2011-07-26 2013-07-20 Общество с ограниченной ответственностью "Инмед" Раствор для получения материала на основе хитозана, способ получения гемостатического материала из этого раствора (варианты) и медицинское изделие с использованием волокон на основе хитозана
CN103975100A (zh) 2011-08-30 2014-08-06 康奈尔大学 金属和陶瓷纳米纤维
US20130237609A1 (en) * 2011-10-19 2013-09-12 Kevin J. Edgar Cellulose derivatives for enhancing bioavailability of flavonoids
CN102560887B (zh) * 2012-01-17 2014-01-29 东华大学 负载维生素a和e的丝素蛋白纳米纤维膜及其制备方法
US20130295143A1 (en) * 2012-05-02 2013-11-07 Massachusetts Institute Of Technology Electroprocessing of active pharmaceutical ingredients
CN102631715A (zh) * 2012-05-04 2012-08-15 江南大学 一种抗凝血纳米纤维膜的制备方法
JP6213975B2 (ja) * 2012-09-13 2017-10-18 テイカ製薬株式会社 薬物含有超極細ファイバーおよびその利用
MX359173B (es) 2012-10-12 2018-09-18 Procter & Gamble Composicion para el cuidado personal en la forma de un articulo disoluble.
WO2014066297A1 (fr) * 2012-10-22 2014-05-01 North Carolina State University Matières fibreuses non tissées
JP6067342B2 (ja) * 2012-11-16 2017-01-25 花王株式会社 シート状化粧料
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
WO2014142675A1 (fr) 2013-03-12 2014-09-18 Active Fibres Limited Compositions de nanofibre et bioactives et procédés associés
RU2522216C1 (ru) * 2013-05-13 2014-07-10 Иван Михайлович Афанасов Многослойный материал с хитозановым слоем из нано- и ультратонких волокон
EP2810645B1 (fr) * 2013-06-06 2017-05-24 A. Sezai Sarac Nouveau système de distribution de médicaments
EP2813212A1 (fr) * 2013-06-10 2014-12-17 Zentiva, a.s. Formulation médicinale, employant l'API en nanofibres
TWI480071B (zh) * 2013-06-26 2015-04-11 Univ Nat Yunlin Sci & Tech 具有三維方向性之奈米纖維細胞導管及其無毒之製備方法與應用
CN103405381B (zh) * 2013-08-23 2016-05-25 北京泰克美高新技术有限公司 一种制备无定型态物质的方法
JP6315754B2 (ja) * 2013-10-02 2018-04-25 花王株式会社 シート状化粧料
US10092679B2 (en) 2013-10-18 2018-10-09 Wake Forest University Health Sciences Laminous vascular constructs combining cell sheet engineering and electrospinning technologies
US10653818B2 (en) 2014-01-23 2020-05-19 University Of Florida Research Foundation, Inc. Magnetic nanoparticle embedded nanofibrous membrane
CN114796017A (zh) 2014-04-22 2022-07-29 宝洁公司 可溶性固体结构体形式的组合物
CN106232880A (zh) * 2014-04-22 2016-12-14 宝洁公司 长丝和使用其的纤维结构
US9867762B2 (en) 2014-05-05 2018-01-16 The Procter & Gamble Company Consumer product comprising a porous dissolvable solid structure and silicone conditioning agent coating
US9827173B2 (en) 2014-05-05 2017-11-28 The Procter & Gamble Company Porous dissolvable solid structure with two benefit agents and methods of forming an aqueous treatment liquor therefrom
US9937111B2 (en) 2014-05-05 2018-04-10 The Procter & Gamble Company Consumer product comprising a fibrous web solid structure with a silicone conditioning agent coating
US9861559B2 (en) 2014-05-05 2018-01-09 The Procter & Gamble Company Consumer product comprising a porous, dissolvable, fibrous web solid structure with a silicone coating
US10213960B2 (en) 2014-05-20 2019-02-26 Massachusetts Institute Of Technology Plasticity induced bonding
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (fr) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Procédés et compositions pour augmenter l'activité biologique de nutriments
CN105362269A (zh) * 2014-09-01 2016-03-02 天津药物研究院 一种含蔗糖的罗氟司特片及其制备方法
CN104383596A (zh) * 2014-10-24 2015-03-04 东华大学 一种tpgs载药脂质体-天然材料复合纳米纤维支架的制备方法
CA2993377C (fr) * 2015-11-19 2019-11-12 Afyx Therapeutics A/S Composition pharmaceutique comprenant des fibres obtenues par un procede electrohydrodynamique, presentant un temps de sejour ameliore sur le site d'application
BR112019014236A2 (pt) 2017-01-23 2020-03-17 Afyx Therapeutics A/S Método para a fabricação de um produto de duas camadas à base de fibras eletrofiadas
KR102595001B1 (ko) 2017-01-23 2023-10-26 에이에프와이엑스 테라퓨틱스 에스에이 높은 함량의 생체접착성 물질을 가지는 전기방사 섬유의 제조 방법
EP3573722B1 (fr) 2017-01-27 2022-02-23 The Procter & Gamble Company Compositions sous forme de structures solides solubles comprenant des particules agglomérées effervescentes
CN110191700A (zh) 2017-01-27 2019-08-30 宝洁公司 可溶性固体结构形式的组合物
JP2018177724A (ja) * 2017-04-18 2018-11-15 花王株式会社 外用薬
EP3624765A1 (fr) 2017-05-16 2020-03-25 The Procter and Gamble Company Compositions de conditionnement pour soins capillaires sous la forme de structures solides solubles
CN107447366A (zh) * 2017-08-03 2017-12-08 东华大学 一种pH敏感载药缓释纳米纤维膜及其制备方法和应用
WO2019147532A1 (fr) 2018-01-26 2019-08-01 The Procter & Gamble Company Articles en dose unitaire soluble dans l'eau comprenant un parfum
CN111556891B (zh) 2018-01-26 2021-11-05 宝洁公司 包含酶的水溶性单位剂量制品
US20190233785A1 (en) 2018-01-26 2019-08-01 The Procter & Gamble Company Water-soluble unit dose articles comprising perfume
CA3086689C (fr) 2018-01-26 2023-05-09 The Procter & Gamble Company Procede de fabrication d'articles hydrosolubles en coupant une toile fibreuse en motif carrele
WO2019168829A1 (fr) 2018-02-27 2019-09-06 The Procter & Gamble Company Produit de consommation comprenant un conditionnement plat contenant des articles de dose unitaire
RU2671738C1 (ru) * 2018-02-28 2018-11-06 Общество с ограниченной ответственностью "Фибрасофт" Способ получения свободно позиционируемых пленок методом электроспиннинга
CN108403657A (zh) * 2018-04-04 2018-08-17 浙江大学 一种口服胶囊
CN108635336A (zh) * 2018-04-04 2018-10-12 浙江大学 一种混合柔性缓释口服胶囊
CN108635337A (zh) * 2018-04-04 2018-10-12 浙江大学 一种柔性复合缓释口服胶囊
US11992560B2 (en) 2018-06-14 2024-05-28 Alma Mater Studiorum—Università di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
EP3583954A1 (fr) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions d'extrait d'écorce de bouleau, fibres électrofilées contenant ces nanodispersions et leur utilisation pour le traitement de plaies
JP1639110S (fr) 2018-07-16 2019-08-13
US10982176B2 (en) 2018-07-27 2021-04-20 The Procter & Gamble Company Process of laundering fabrics using a water-soluble unit dose article
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
US12234431B2 (en) 2018-10-03 2025-02-25 The Procter & Gamble Company Water-soluble unit dose articles comprising water-soluble fibrous structures and particles
CN113748195B (zh) 2019-01-28 2024-01-19 宝洁公司 可回收利用的、可再生的或可生物降解的包装
EP3712237A1 (fr) 2019-03-19 2020-09-23 The Procter & Gamble Company Articles fibreux de dose unitaire soluble dans l'eau comprenant des structures fibreuses solubles dans l'eau
US12031254B2 (en) 2019-03-19 2024-07-09 The Procter & Gamble Company Process of reducing malodors on fabrics
CN114206307B (zh) 2019-06-28 2024-08-23 宝洁公司 包含阴离子表面活性剂的可溶性固体纤维制品
MX2021015391A (es) 2019-07-03 2022-01-24 Procter & Gamble Estructuras fibrosas que contienen surfactantes cationicos y acidos solubles.
USD939359S1 (en) 2019-10-01 2021-12-28 The Procter And Gamble Plaza Packaging for a single dose personal care product
US11597191B2 (en) 2019-10-14 2023-03-07 The Procter & Gamble Company Biodegradable and/or home compostable sachet containing a solid article
EP4061320B1 (fr) 2019-11-20 2024-07-03 The Procter & Gamble Company Structure solide poreuse soluble
CN114929182B (zh) 2019-12-01 2024-05-28 宝洁公司 具有含有苯甲酸钠和二醇和/或甘油酯的防腐体系的毛发调理剂组合物
CN111020880A (zh) * 2019-12-04 2020-04-17 广西民族大学 结肠靶向盐酸青藤碱缓释纳米纤维膜及其制备方法和应用
USD962050S1 (en) 2020-03-20 2022-08-30 The Procter And Gamble Company Primary package for a solid, single dose beauty care composition
USD941051S1 (en) 2020-03-20 2022-01-18 The Procter And Gamble Company Shower hanger
USD965440S1 (en) 2020-06-29 2022-10-04 The Procter And Gamble Company Package
CN115867357A (zh) 2020-07-31 2023-03-28 宝洁公司 用于毛发护理的含有球粒的水溶性纤维小袋
CN116472021A (zh) 2020-08-11 2023-07-21 宝洁公司 含有芸苔油醇缬氨酸酯乙磺酸盐的清洁冲洗毛发调理剂组合物
US11633336B2 (en) 2020-08-11 2023-04-25 The Procter & Gamble Company Low viscosity hair conditioner compositions containing brassicyl valinate esylate
EP4196233A1 (fr) 2020-08-11 2023-06-21 The Procter & Gamble Company Compositions d'après-shampooing hydratant contenant de l'ésylate de valinate de brassicyle (bve)
JP7605842B2 (ja) 2020-08-19 2024-12-24 ザ プロクター アンド ギャンブル カンパニー 直接添加マイクロカプセルを含有する可撓性多孔質溶解性固体シート物品及びそれを作製するための方法
CN116568266A (zh) 2020-12-01 2023-08-08 宝洁公司 含有溶解的去头皮屑活性物质的含水毛发调理剂组合物
MX2023006721A (es) 2020-12-08 2023-07-04 Todd Frank Ovokaitys Metodos y sistemas para producción incrementada de celulas madre.
USD1045064S1 (en) 2020-12-17 2024-10-01 The Procter & Gamble Company Single-dose dissolvable personal care unit
EP4395730A1 (fr) 2021-08-30 2024-07-10 The Procter & Gamble Company Structure solide soluble comprenant des premier et second agents structurants polymères
EP4447893A1 (fr) 2021-12-17 2024-10-23 The Procter & Gamble Company Articles de shampooing fibreux solides solubles contenant des sels
WO2023117590A1 (fr) * 2021-12-21 2023-06-29 Universiteit Gent Fibres électrofilées en solution, compositions les comprenant et leur procédé de fabrication
JPWO2023145886A1 (fr) * 2022-01-31 2023-08-03
EP4489719A1 (fr) 2022-03-10 2025-01-15 The Procter & Gamble Company Structure solide soluble ayant des première et seconde couches
CN114522166B (zh) * 2022-04-22 2022-09-30 北京剂泰医药科技有限公司 一种固体分散体组合物及其制备方法和应用
CN116898820A (zh) * 2023-07-12 2023-10-20 浙江亚瑟医药有限公司 一种基于静电纺丝技术制备环孢素固体分散体的方法
CN118750469B (zh) * 2024-06-12 2025-09-26 华中农业大学 一种尺寸可控的噬菌体水凝胶微球及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US17208A (en) * 1857-05-05 Improvement in heating feed-water apparatus of locomotives
US5034421A (en) * 1988-12-13 1991-07-23 Fuisz Pharmaceutical Ltd. Moderated spun fibrous system and method of manufacture
US5024789A (en) * 1988-10-13 1991-06-18 Ethicon, Inc. Method and apparatus for manufacturing electrostatically spun structure
US5311884A (en) * 1991-11-12 1994-05-17 Ethicon, Inc. Process for making a piezoelectric biomedical device
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US6106913A (en) * 1997-10-10 2000-08-22 Quantum Group, Inc Fibrous structures containing nanofibrils and other textile fibers
US6110590A (en) * 1998-04-15 2000-08-29 The University Of Akron Synthetically spun silk nanofibers and a process for making the same
US6753454B1 (en) * 1999-10-08 2004-06-22 The University Of Akron Electrospun fibers and an apparatus therefor
CA2396640A1 (fr) * 2000-01-28 2001-08-02 Smithkline Beecham Corporation Compositions pharmaceutiques soumises au filage electrique
JP4290980B2 (ja) * 2000-10-18 2009-07-08 ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション 薬剤送達および細胞被包における電気処理
WO2003099230A2 (fr) * 2002-05-28 2003-12-04 Virginia Commonwealth University Intellectual Property Foundation Collagene soumis a un traitement electrique et tissus produits par genie biologique

Also Published As

Publication number Publication date
CN1684673A (zh) 2005-10-19
EP1534250A2 (fr) 2005-06-01
WO2004014304A2 (fr) 2004-02-19
TW200410714A (en) 2004-07-01
CA2494865A1 (fr) 2004-02-19
IS7722A (is) 2005-03-01
BR0313222A (pt) 2005-06-14
NO20051123L (no) 2005-05-06
AU2003258120A1 (en) 2004-02-25
AR040820A1 (es) 2005-04-20
US20060013869A1 (en) 2006-01-19
RU2005106261A (ru) 2005-08-10
IL166465A0 (en) 2006-01-15
WO2004014304A3 (fr) 2004-06-24
NZ537951A (en) 2007-12-21
ZA200500563B (en) 2006-07-26
EP1534250A4 (fr) 2007-07-04
KR20050055696A (ko) 2005-06-13
AU2003258120B2 (en) 2009-02-26
JP2005534716A (ja) 2005-11-17
MXPA05001499A (es) 2005-04-19
PL374800A1 (en) 2005-10-31
RU2331411C2 (ru) 2008-08-20

Similar Documents

Publication Publication Date Title
MA27332A1 (fr) Compositions pharmaceutiques amorphes electroniquement filees.
Gavel et al. Investigations of peptide-based biocompatible injectable shape-memory hydrogels: differential biological effects on bacterial and human blood cells
Gabriel et al. Synthetic mimic of antimicrobial peptide with nonmembrane-disrupting antibacterial properties
Yu et al. Nanofibers fabricated using triaxial electrospinning as zero order drug delivery systems
KR101592659B1 (ko) 활성 약학적, 생물학적, 영양학적 및 에너지적 조성의 다형성 극복 및 향상된 특성 부여를 위한 다관능성 이온성 액체 조성물
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
Partheniadis et al. Essential oil—loaded nanofibers for pharmaceutical and biomedical applications: a systematic mini-review
BRPI0411678A (pt) nanopartìculas de ácido hialurÈnico
DE60023520D1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1832289A3 (fr) Compositions et revêtements pour dispositifs médicaux implantables
EP1988910A4 (fr) Conjugués de polymères contenant de l'acryloyloxyéthylphosphorylcholine et leur préparation
CA2462606A1 (fr) Compositions liquides pour administration par voie orale, a base de guaifenesine et d'un copolymere bloc de polyoxyalkylene
MA31898B1 (fr) Compositions pharmaceutiques
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
BR9900116A (pt) Comprimido de mesilato de trovafloxacina.
MD3866B1 (en) 5,4Æ-dimethylcampherol 3-O-Beta-D-(6ÆÆ-AlphaÆ-LÆ -rhamnopyranosyl)-glucopyranoside as compound increasing the seed productivity
DE602006018467D1 (de) Schnell lösliche Formulierung von nichtsteroidalen Antiphlogistika
Lokesh et al. Enhanced cytotoxic effect of chemically conjugated polymeric sirolimus against ht-29 colon cancer and a-549 lung cancer cell lines
Birer et al. Telmisartan loaded polycaprolactone/gelatin-based electrospun vascular scaffolds
EP2241571A4 (fr) 6-méthoxy-2',3'-didésoxyguanosine stable, son procédé de préparation et composition pharmaceutique la contenant
FR2791980B1 (fr) Pyrido-thieno-diazepines, leur procede de preparation, et les compositions pharmaceutiques les contenant